Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drugs In Development, 2022, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline landscape.
Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 22, 6 and 4 respectively.
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Overview
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Companies Involved in Therapeutics Development
3SBio Inc
Adaptimmune Therapeutics Plc
Advenchen Laboratories LLC
Aldeyra Therapeutics Inc
Apexian Pharmaceuticals Inc
Ascentage Pharma Group International
AstraZeneca Plc
BeiGene Ltd
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Eisai Co Ltd
Epizyme Inc
F. Hoffmann-La Roche Ltd
Jiangsu Hengrui Medicine Co Ltd
Karyopharm Therapeutics Inc
Merck & Co Inc
Mirati Therapeutics Inc
Moleculin Biotech Inc
Novartis AG
Oncomatryx Biopharma SL
Open Therapeutics LLC
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sino Biopharmaceutical Ltd
Sorrento Therapeutics Inc
Tango Therapeutics Inc
Vyriad Inc
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drug Profiles
(cedazuridine + decitabine) - Drug Profile
Product Description
Mechanism Of Action
afamitresgene autoleucel - Drug Profile
Product Description
Mechanism Of Action
AL-2846 - Drug Profile
Product Description
Mechanism Of Action
Annamycin - Drug Profile
Product Description
Mechanism Of Action
APG-115 - Drug Profile
Product Description
Mechanism Of Action
APX-3330 - Drug Profile
Product Description
Mechanism Of Action
axitinib - Drug Profile
Product Description
Mechanism Of Action
camrelizumab - Drug Profile
Product Description
Mechanism Of Action
cobimetinib fumarate - Drug Profile
Product Description
Mechanism Of Action
CS-2164 - Drug Profile
Product Description
Mechanism Of Action
ecubectedin - Drug Profile
Product Description
Mechanism Of Action
eribulin mesylate - Drug Profile
Product Description
Mechanism Of Action
everolimus - Drug Profile
Product Description
Mechanism Of Action
ganetespib - Drug Profile
Product Description
Mechanism Of Action
HSV-1716 - Drug Profile
Product Description
Mechanism Of Action
ipilimumab - Drug Profile
Product Description
Mechanism Of Action
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
MRTX-9768 - Drug Profile
Product Description
Mechanism Of Action
OMTX-703 - Drug Profile
Product Description
Mechanism Of Action
Oncolytic Virus to Activate TIMP3 for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumor - Drug Profile
Product Description
Mechanism Of Action
Oncolytic Virus to Target CD46 and SLC5A5 for Oncology - Drug Profile
Product Description
Mechanism Of Action
pamiparib - Drug Profile
Product Description
Mechanism Of Action
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
pexidartinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
sapanisertib - Drug Profile
Product Description
Mechanism Of Action
selinexor - Drug Profile
Product Description
Mechanism Of Action
selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
sitravatinib malate - Drug Profile
Product Description
Mechanism Of Action
SSGJ-609A - Drug Profile
Product Description
Mechanism Of Action
tazemetostat hydrobromide - Drug Profile
Product Description
Mechanism Of Action
telaglenastat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
TNG-908 - Drug Profile
Product Description
Mechanism Of Action
TQB-3234 - Drug Profile
Product Description
Mechanism Of Action
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by 3SBio Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Adaptimmune Therapeutics Plc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Advenchen Laboratories LLC, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Aldeyra Therapeutics Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Apexian Pharmaceuticals Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Ascentage Pharma Group International, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by AstraZeneca Plc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by BeiGene Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Bristol-Myers Squibb Co, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Calithera Biosciences Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Eisai Co Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Epizyme Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Karyopharm Therapeutics Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Merck & Co Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Mirati Therapeutics Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Moleculin Biotech Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Novartis AG, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Oncomatryx Biopharma SL, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Open Therapeutics LLC, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Otsuka Pharmaceutical Co Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pfizer Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pharma Mar SA, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Plexxikon Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Sino Biopharmaceutical Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Sorrento Therapeutics Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Tango Therapeutics Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Vyriad Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
